Felzartamab
Tīmeklis2024. gada 21. okt. · Felzartamab (MOR202/TJ202) is a therapeutic human monoclonal antibody derived from MorphoSys' HuCAL antibody library and directed against CD38. In IgAN, plasma cells have a dual role in the development and progression of the disease through an excessive secretion of both the pathogenic IgA1 and its autoantibodies. … Tīmeklis2024. gada 12. apr. · Felzartamab是一种用于耗竭CD38+浆细胞的在研单克隆抗体，这些浆细胞被认为通过产生抗PLA2R（aPLA2R）自身抗体推动原发性膜性肾病（PMN）的发生。根据此积极结果，HI-Bio计划将felzartamab推进到后期试验。 PMN是一种影响肾功能的罕见内分泌代谢疾病。
Felzartamab
Did you know?
Felzartamab overview Felzartamab is under development for the treatment of late antibody-mediated renal allograft rejection, IgA nephropathy (IgAN), membranous nephropathy(anti-PLA2R antibody-positive membranous nephropathy), refractory/relapsed multiple myeloma and systemic lupus erythematosus. Tīmeklis2024. gada 11. apr. · About Felzartamab. Felzartamab is an investigational therapeutic human monoclonal antibody directed against CD38, a protein expressed on mature …
Tīmeklis天境生物宣布差异化CD38抗体菲泽妥单抗的多项注册临床研究进展. - 菲泽妥单抗与另一款自研产品联用多发性骨髓瘤一线治疗的IND申请计划于年内递交，以布局多发性骨 … Tīmeklis2024. gada 8. apr. · Discussion Based on the hypothesis that felzartamab is able to halt the progression of ABMR via targeting antibody-producing PC and NK cells, we believe that our trial could potentially provide ...
Tīmeklis2024. gada 12. apr. · Felzartamab是一种用于耗竭CD38+浆细胞的在研单克隆抗体，这些浆细胞被认为通过产生抗PLA2R（aPLA2R）自身抗体推动原发性膜性肾 … Tīmeklis2024. gada 20. okt. · About Felzartamab Felzartamab (MOR202/TJ202) is a therapeutic human monoclonal antibody derived from MorphoSys' HuCAL antibody library and directed against CD38. In IgAN, plasma cells have a dual role in the development and progression of the disease through an excessive secretion of both …
Tīmeklis2024. gada 15. jūn. · Felzartamab (TJ202/MOR202) is an investigational human monoclonal antibody derived from MorphoSys’ HuCAL® antibody technology. The …
Tīmeklis2024. gada 14. jūn. · About Felzartamab Felzartamab (MOR202) is a therapeutic human monoclonal antibody derived from MorphoSys’ HuCAL antibody library and directed against CD38. In Membranous Nephropathy, long-lived plasma cells drive pathogenic antibody production, contributing to functional damage to the glomeruli in … foxit pdf editor chineseTīmeklis2024. gada 4. nov. · About Felzartamab Felzartamab (MOR202/TJ202) is a therapeutic human monoclonal antibody derived from MorphoSys' HuCAL antibody library and directed against CD38. In Membranous Nephropathy, long-lived plasma cells drive pathogenic antibody production, contributing to functional damage to the glomeruli in … black under cabinet microwaveTīmeklis2024. gada 13. maijs · Felzartamab (MOR202) is a therapeutic human monoclonal antibody derived from MorphoSys' HuCAL antibody library and directed against … foxit pdf editor couponTīmeklisFelzartamab is a therapeutic human monoclonal antibody directed against CD38. Human Immunology Biosciences, Inc. (HI-Bio) obtained exclusive rights to develop … black under armour tracksuitTīmeklisFelzartamab is a therapeutic human monoclonal antibody directed against CD38. Human Immunology Biosciences, Inc. (HI-Bio) obtained exclusive rights to develop and commercialize felzartamab across all indications worldwide, with the exception of Greater China. During a transition phase, MorphoSys is evaluating felzartamab for … foxit pdf editor compress pdfTīmeklisFelzartamab is an antibody directed against CD38, a protein expressed on the surface of mature plasma cells. When applied, felzartamab is believed to deplete plasma … foxit pdf editor alternativeTīmeklis2024. gada 14. jūn. · Felzartamab (MOR202) is a therapeutic human monoclonal antibody derived from MorphoSys’ HuCAL antibody library and directed against CD38. In Membranous Nephropathy, long-lived plasma cells drive ... black under brown hair